The Impact of COVID-19 is included in Adalimumab Biosimilar Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Adalimumab Biosimilar Trends and Forecast
The future of the global adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets. The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030 with a CAGR of 21.6% from 2024 to 2030. The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Adalimumab Biosimilar by Segment
The study includes a forecast for the global adalimumab biosimilar by product, end use, and region.
Adalimumab Biosimilar Market by Product [Shipment Analysis by Value from 2018 to 2030]:
• Exemptia
• Adalirel
• Cipleumab
• Others
Adalimumab Biosimilar Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
• Hospitals Pharmacies
• Retail Pharmacies
• Others
Adalimumab Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Adalimumab Biosimilar Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adalimumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adalimumab biosimilar companies profiled in this report include-
• Alfred E. Tiefenbacher
• Amgen
• Boehringer Ingelheim
• Glenmark
• Zydus
• Torrent Pharmaceuticals
• Reliance Life Sciences
Adalimumab Biosimilar Market Insights
Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.
Within this market, hospitals pharmacies is expected to remain the largest segment due to the fact that adalimumab biosimilars are used to treat a variety of autoimmune diseases, which are typically managed by specialists in hospital settings.
North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.
Features of the Global Adalimumab Biosimilar Market
Market Size Estimates: Adalimumab biosimilar market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Adalimumab biosimilar market size by product, end use, and region in terms of value ($B).
Regional Analysis: Adalimumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different products, end uses, and regions for the adalimumab biosimilar market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adalimumab biosimilar market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the adalimumab biosimilar market size?
Answer: The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030.
Q2. What is the growth forecast for adalimumab biosimilar market?
Answer: The global adalimumab biosimilar market is expected to grow with a CAGR of 21.6% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the adalimumab biosimilar market?
Answer: The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.
Q4. What are the major segments for adalimumab biosimilar market?
Answer: The future of the adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets.
Q5. Who are the key adalimumab biosimilar market companies?
Answer: Some of the key adalimumab biosimilar companies are as follows:
• Alfred E. Tiefenbacher
• Amgen
• Boehringer Ingelheim
• Glenmark
• Zydus
• Torrent Pharmaceuticals
• Reliance Life Sciences
Q6. Which adalimumab biosimilar market segment will be the largest in future?
Answer: Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.
Q7. In adalimumab biosimilar market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the adalimumab biosimilar market by product (exemptia, adalirel, cipleumab, and others), end use (hospitals pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Adalimumab Biosimilar Market, Adalimumab Biosimilar Market Size, Adalimumab Biosimilar Market Growth, Adalimumab Biosimilar Market Analysis, Adalimumab Biosimilar Market Report, Adalimumab Biosimilar Market Share, Adalimumab Biosimilar Market Trends, Adalimumab Biosimilar Market Forecast, Adalimumab Biosimilar Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Adalimumab Biosimilar Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Adalimumab Biosimilar Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Adalimumab Biosimilar Market by Product
3.3.1: Exemptia
3.3.2: Adalirel
3.3.3: Cipleumab
3.3.4: Others
3.4: Global Adalimumab Biosimilar Market by End Use
3.4.1: Hospitals Pharmacies
3.4.2: Retail Pharmacies
3.4.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Adalimumab Biosimilar Market by Region
4.2: North American Adalimumab Biosimilar Market
4.2.2: North American Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
4.3: European Adalimumab Biosimilar Market
4.3.1: European Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
4.3.2: European Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
4.4: APAC Adalimumab Biosimilar Market
4.4.1: APAC Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
4.4.2: APAC Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
4.5: ROW Adalimumab Biosimilar Market
4.5.1: ROW Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
4.5.2: ROW Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Adalimumab Biosimilar Market by Product
6.1.2: Growth Opportunities for the Global Adalimumab Biosimilar Market by End Use
6.1.3: Growth Opportunities for the Global Adalimumab Biosimilar Market by Region
6.2: Emerging Trends in the Global Adalimumab Biosimilar Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Adalimumab Biosimilar Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Adalimumab Biosimilar Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Alfred E. Tiefenbacher
7.2: Amgen
7.3: Boehringer Ingelheim
7.4: Glenmark
7.5: Zydus
7.6: Torrent Pharmaceuticals
7.7: Reliance Life Sciences
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Adalimumab Biosimilar Market Report.